David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...

JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Demand GLP-1 Medications as Prescription Drug Market GrowsSchaumburg, Illinois, Feb 21, 2025 - (ACN Newswire) - Giftify, Inc.

The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.

The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...